This is an open access article distributed under the terms of the CC-BY license, which permits unrestricted use, distribution, and reproduction in any medium. You are not required to obtain permission to reuse this article content, provided that you credit the author and journal.
JAMA Health Forum
EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, MARCH 11, 2022
Media advisory: The full study is linked to this news release.
About JAMA Health Forum: JAMA Health Forum has transitioned from an information channel to an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.
What The Study Did: Researchers examined whether Medicaid patients in Wisconsin with opioid use disorder experienced decreased access to treatment, including receiving buprenorphine and urine drug testing during the COVID-19 pandemic.
Authors: Alyssa Shell Tilhou, M.D., Ph.D., of the Boston University School of Medicine/Boston Medical Center, is the corresponding author.
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.
Tilhou AS, Dague L, Saloner B, Beemon D, Burns M. Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic. JAMA Health Forum. 2022;3(3):e220093. doi:10.1001/jamahealthforum.2022.0093
Download citation file: